SCHEMBL6400541

SCHEMBL6400541

O=C(Nc1cc(F)cc(N2CCOCC2)c1)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.59
GPR183 P32249 1/20 0.55
RAB9A P51151 9/20 0.55
MAPT P10636 8/20 0.55
NPC1 O15118 8/20 0.55
SMN1; SMN2 Q16637 7/20 0.55
ALDH1A1 P00352 2/20 0.55
EPHX1 P07099 1/20 0.55
DGAT1 O75907 1/20 0.55
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
TP53 P04637 4/20 0.53
PKM P14618 2/20 0.53
NFKB1 P19838 2/20 0.53
NFKB2 Q00653 2/20 0.53
RELA Q04206 2/20 0.53
ATM Q13315 1/20 0.53
MAPK1 P28482 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HTT P42858 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6883068 0.85 SMN1; SMN2 (0.54) PLAUGPR183RAB9AMAPTNPC1
SCHEMBL16106995 0.84 GPR183 (0.59) PLAUGPR183RAB9AMAPTNPC1
SCHEMBL6424561 0.83 KMO (0.63) RAB9AMAPTNPC1SMN1; SMN2ALDH1A1
SCHEMBL2565238 0.83 HDAC8 (0.76) RAB9AMAPTNPC1SMN1; SMN2ALDH1A1
SCHEMBL2977919 0.81 PLAU (0.55) PLAUGPR183RAB9AMAPTNPC1
SCHEMBL2979404 0.80 SMN1; SMN2 (0.56) PLAURAB9AMAPTNPC1SMN1; SMN2
SCHEMBL4252909 0.80 HDAC8 (0.76) RAB9AMAPTNPC1SMN1; SMN2ALDH1A1
SCHEMBL28741190 0.79 RAB9A (0.51) PLAUGPR183RAB9AMAPTNPC1
SCHEMBL12764328 0.78 BRAF (0.59) PLAURAB9AMAPTNPC1SMN1; SMN2
SCHEMBL30455592 0.78 NPC1 (0.74) RAB9ANPC1SMN1; SMN2L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1102743-B1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2002-07-24 EP claimed
CN-1243724-C Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2006-03-01 CN disclosed
US-20050245551-A1 Amide derivatives ASTRAZENECA AB 2005-11-03 US disclosed
CN-1178932-C Amide derivatives 2004-12-08 CN disclosed
EP-1163237-B1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2004-05-06 EP disclosed
EP-1102743-B1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2002-07-24 EP disclosed
CN-1350530-A Amide derivatives ASTRAZENECA AB (SE) 2002-05-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245551-A1 Amide derivatives IL6, IL6ST, IL1B PLAU 3125/4885GPR183 2733/4885RAB9A 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.